Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.24% | -28.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.08% | 8.95% | |||
| Operating Income | 0.08% | -8.95% | |||
| Income Before Tax | -530.64% | 122.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -530.64% | 122.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -530.64% | 122.30% | |||
| EBIT | 0.08% | -8.95% | |||
| EBITDA | 0.32% | -8.90% | |||
| EPS Basic | -507.55% | 122.32% | |||
| Normalized Basic EPS | -509.09% | 122.22% | |||
| EPS Diluted | -507.55% | 122.32% | |||
| Normalized Diluted EPS | -509.09% | 122.22% | |||
| Average Basic Shares Outstanding | 5.55% | 0.23% | |||
| Average Diluted Shares Outstanding | 5.55% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||